Cyclic antidepressants and the risk of sudden cardiac death

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 234-241

  Ray, Wayne A ^a   Meredith, Sarah ^b   Thapa, Purushottam B ^b   Hall, Kathi ^b   Murray, Katherine T ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COHORT STUDIES; CONFIDENCE INTERVALS; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 1542316301     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.09.019     Document Type: Article

References (48)

1. Glassman A.H., Preud'homme X.A. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry. 54:(Suppl):1993;16-22.
2. Teschemacher A.G., Seward E.P., Hancox J.C., Witchel H.J. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 128:1999;479-485.
3. Roose S.P., Glassman A.H., Giardina E.G.V., Johnson L.L., Walsh B.T., Bigger J.T. Jr. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol. 7:1987;247-251.
4. Roose S.P., Laghrissi-Thode F., Kennedy J.S., Nelson C., Bigger J.T., Pollock B.G., et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 279:1998;287-291.
5. Coupland N., Wilson S., Nutt D. Antidepressant drugs and the cardiovascular system a comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol. 11:1997;83-92.
6. Roose S.P., Spatz E. Treatment of depression in patients with heart disease. J Clin Psychiatry. 60:(Suppl):1999;34-37.
7. Glassman A.H., Rodriguez A.I., Shapiro P.A. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry. 59:(Suppl):1998;16-21.
8. Su-Hyun J., Youm J.B., Lee C.O., Earm Y.E., Ho W.K. Blockade of the HERG human cardiac K+ channel by the antidepressant drug amitriptyline. Br J Pharmacol. 129:2000;1474-1480.
9. Studenik C., Lemmens-Gruber R., Heistracher P. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci. 7:1999;113-118.
10. Reilly J.G., Ayis S.A., Ferrier I.N., Jones S.J., Thomas H.L. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 355:2000;1048-1052.
11. Strasberg B., Coelho A., Welch W., Swiryn S., Bauernfeind R., Rosen K. Doxepin induced torsade de pointes. Pacing Clin Electrophysiol. 5:1982;873-877.
12. Tzivoni D., Keren A., Cohen A.M., Loebel H., Zahavi I., Chenzbraun A., et al. Magnesium therapy for torsades de pointes. Am J Cardiol. 53:1984;528-530.
13. Herrmann H.C., Kaplan L.M., Bierer B.E. QT prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol. 51:1983;904-906.
14. Dorsey S.T. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med. 18:2000;227-229.
15. Glassman A.H., Roose S.P., Bigger J.T. The safety of tricyclic antidepressants in cardiac patients risk-benefit reconsidered. JAMA. 269:1993;2673-2675.
16. Nau C., Seaver M., Wang S., Wang G. Block of human heart hH1 sodium channels by amitriptyline. J Pharmacol Exp Ther. 292:2000;1015-1023.
17. Witchel H.J., Hancox J.C., Nutt D.J. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 23:2003;58-77.
18. Moir D.C., Cornwell W.B., Dingwall-Fordyce I., Crooks J., O'Malley K., Turnbull M.J., et al. Cardiotoxicity of amitriptyline. Lancet. 2:1972;561-564.
19. Adverse reactions to the tricyclic-antidepressant drugs. Report from Boston Collaborative Drug Surveillance Program. Lancet 1972;1:529-31
20. Kuhs H., Rudolf G.A.E. Cardiovascular effects of paroxetine. Psychopharmacology. 102:1990;379-382.
21. Reynolds C.F. III, Regestein Q., Nowell P.D., Neylan T.C. Treatment of insomnia in the elderly. Salzman C. Clinical geriatric psychopharmacology. 1998;395-416 Williams & Wilkins, Boston (MA).
22. Deleu D., Hanssens Y., Worthing E.A. Symptomatic and prophylactic treatment of migraine a critical reappraisal. Clin Neuropharmacol. 21:1998;267-279.
23. Bryson H.M., Wilde M.I. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 8:1996;459-476.
24. Hannonen P., Malminiemi K., Yli-Kerttula U., Isomeri R., Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 37:1998;1279-1286.
25. Rajagopalan M., Kurian G., John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol. 13:1998;738-741.
26. Ray W.A., Griffin M.R. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 129:1989;837-849.
27. Ray W.A., Meredith S., Thapa P.B., Meador K.G., Hall K., Murray K.T. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 58:2001;1161-1167.
28. Piper J.M., Ray W.A., Griffin M.R., Fought R., Daugherty J.R., Mitchel E. Jr. Methodological issues in evaluating expanded Medicaid coverage for pregnant women. Am J Epidemiol. 132:1990;561-571.
29. Strom B.L., Carson J.L. Use of automated databases for pharmacoepidemiology research. Armenian H.K., Gordis L., Levine M.M., Thacker S.B. Epidemiologic reviews. 1990;87-107 The Johns Hopkins University School of Hygiene and Public Health, Baltimore (MD).
30. West S.L., Savitz D.A., Koch G., Strom B.L., Guess H.A., Hartzema A. Recall accuracy for prescription medications self-report compared with database information. Am J Epidemiol. 142:1995;1103-1110.
31. Landry MA, Smyer MA. Home visit medicine use validation study. Medicine, health and aging: enrollment in Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE) Program. University Park (PA): The Pennsylvania State University; 1986
32. Leister K.A., Edwards W.A., Christensen D.B. A comparison of patient drug regimens as viewed by the physician, pharmacist and patient. Med Care. 24:1981;658-664.
33. Johnson R.E., Vollmer W.M. Comparing sources of drug data about the elderly. J Am Geriatr Soc. 39:1991;1079-1084.
34. Small G.W., Salzman C. Treatment of depression with new and atypical antidepressants. Salzman C. Clinical geriatric psychopharmacology. 1998;245-261 Williams & Wilkins, Boston (MA).
35. American Medical Association. Drug evaluations annual 1995. Chicago: American Medical Association; 1995
36. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders. Hardman J.G., Limbird L.E., Gilman A.G. Goodman & Gillman's the pharmacological basic of therapeutics. 2001;447-483 McGraw-Hill, New York.
37. Marcus F.I., Cobb L.A., Edwards J.E., Kuller L., Moss A.J., Bigger J.T., et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol. 61:1988;8-15.
38. Hinkle L.E., Thaler H.T. Clinical classification of cardiac deaths. Circulation. 65:1982;457-464.
39. Siscovick D.S., Raghunathan T.E., Psaty B.M., Koepsell T.D., Wicklund K.G., Lin X., et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 330:1994;1852-1857.
40. Albert C.M., Hennekens C.H., O'Donnell C.J., Ajani U.A., Carey V.J., Willett W.C., et al. Fish consumption and risk of sudden cardiac death. JAMA. 279:1998;23-28.
41. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., Lehmann M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 270:1993;2590-2597.
42. Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death epidemiology, transient risk, and intervention assessment. Ann Intern Med. 119:1993;1187-1197.
43. Roose S.P., Glassman A.H., Giardina E.G.V., Walsh T., Woodring S., Bigger J.T. Jr. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry. 44:1987;273-275.
44. Jenkins R., Bebbington P., Brugha T.S., Farrell M., Lewis G., Meltzer H. British psychiatric morbidity survey. Br J Psychiatry. 173:1998;4-7.
45. Frasure-Smith N., Lesperance F., Talajic M. Depression following myocardial infarction impact on 6-month survival. JAMA. 270:1993;1819-1825.
46. Iglehart J.K. The dilemma of medicaid. N Engl J Med. 348:2003;2140-2148.
47. Carr R.M., Christiansen B., Jehn L., Matitz D. Meeting the challenge of tobacco use within the Medicaid population. WMJ. 100:2001;59-66.
48. Holahan J. Health status and the cost of expanding insurance coverage. Health Aff (Millwood). 20:2001;279-286.